Scienza e Tecnologia
Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella
Measles and Rubella vaccines are typically maintained in a lyophilized (freeze-dried) form that requires reconstitution in solution prior to injection using a needle and syringe. Once reconstituted, however, the vaccines exhibit very poor thermal stability and rapidly lose effectiveness if not refrigerated. This is an important consideration in low- and middle-income countries (LMIC) where cold-chain issues and access to target populations for vaccinations can be challenging.
By eliminating the need for reconstitution and improving thermal stability, ImplaVax®-enabled Measles and Rubella vaccines could improve the cost effectiveness of supply and robustness of vaccine deployment and delivery in these regions. Additionally, ImplaVax®-enabled Measles and Rubella vaccines may provide further benefits that improve vaccination uptake and coverage based on needle-free delivery of a unit dose minimising vaccine wastage, elimination of needlestick and cross contamination hazards and waste, and requirement for minimal training.
Measles remains one of the leading causes of childhood mortality leading to an estimated 450 deaths each day worldwide, according to the World Health Organization. It is highly infectious and serious complications include blindness, encephalitis (brain swelling), ear and respiratory infections.
Rubella is usually a mild infection in childhood however when an unprotected woman is infected while pregnant it can result in miscarriage, serious or sometimes fatal complications for the foetus including hearing, eye and heart defects as well as autism and diabetes.
Measles and rubella infections are preventable through immunisation but because of persistent gaps in immunisation coverage outbreaks of both infections continue to occur, exacerbated by vaccine hesitancy and refusals and gaps in surveillance and reporting.
Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies. These diseases affect millions of people around the world. We work in partnership with global companies, government agencies, leading academic institutions and non-governmental organisations with the goal of making a material and lasting positive impact on global health.
Our award-winning ImplaVax®-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats. ImplaVax® products are designed to enhance the immune response and offer significant benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, reliability and stability, and a strong subject preference over administration using needle and syringe. They can be administered with minimal training and are also rapidly deployable while eliminating the need for cold-chain storage.
Our pipeline targets a range of common and emerging infectious diseases, inflammatory diseases and allergies, and has been established through collaborations with world-class organisations, including BARDA DRIVe*, the Bill & Melinda Gates Foundation, Innovate UK, the University of Oxford , the Walter Reed Army Institute of Research (WRAIR), Sementis and the University of Adelaide .
We are also advancing a number of collaborations with leading organisations in animal health, including The Pirbright Institute, which have generated positive results demonstrating the potential of our ImplaVax® formulation and needle-free delivery technologies.
Enesi's experienced leadership team has a proven track record in the successful development and commercialisation of innovative products delivering high value outcomes for all stakeholders and is supported by a world-renowned Scientific Advisory Board.
David Hipkiss , CEO
Tel: +44 (0) 7968 707072
Email: david.hipkiss@enesipharma.com
Mark Swallow , Nathaniel Dahan
Tel: +44 (0) 20 7638 9571
Email: enesipharma@citigatedewerogerson.com
Web www.enesipharma.com | LinkedIn @EnesiPharma | Twitter @Enesi_Pharma